Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy

Fengzhi Cui; Jianhua Liu; Tianqi Zhang; Siwen Pang; Haijia Yu; Nannan Xu

doi:10.3389/fbioe.2023.1101673

Low-dimensional nanomaterials as an emerging platform for cancer diagnosis and therapy

Front Bioeng Biotechnol. 2023 Jan 19:11:1101673. doi: 10.3389/fbioe.2023.1101673. eCollection 2023.

Authors

Fengzhi Cui¹, Jianhua Liu¹, Tianqi Zhang¹, Siwen Pang¹, Haijia Yu¹, Nannan Xu¹

Affiliation

¹ Department of Radiology, The Second Hospital of Jilin University, Changchun, China.

Abstract

The burden of cancer is increasing, being widely recognized as one of the main reasons for deaths among humans. Despite the tremendous efforts that have been made worldwide to stem the progression and metastasis of cancer, morbidity and mortality in malignant tumors have been clearly rising and threatening human health. In recent years, nanomedicine has come to occupy an increasingly important position in precision oncotherapy, which improves the diagnosis, treatment, and long-term prognosis of cancer. In particular, LDNs with distinctive physicochemical capabilities have provided great potential for advanced biomedical applications, attributed to their large surface area, abundant surface binding sites, and good cellular permeation properties. In addition, LDNs can integrate CT/MR/US/PAI and PTT/PDT/CDT/NDDS into a multimodal theranostic nanoplatform, enabling targeted therapy and efficacy assessments for cancer. This review attempts to concisely summarize the classification and major properties of LDNs. Simultaneously, we particularly emphasize their applications in the imaging, diagnosis, and treatment of cancerous diseases.

Keywords: 0D nanomaterials; 1D nanomaterials; 2D nanomaterials; cancer therapy; imaging.

Publication types

Review

Grants and funding

This work was supported by the National Natural Science Foundation of China (Nos 82071981 and 21635007), the Health Special Project of Jilin Province Department of Finance (Nos 3D518V283429 and 201817301863), and the Fundamental Research Funds for the Central Universities (No. 419070600032).